

Neuroimaging Pharmacopoeia

Daniel Thomas Ginat
Juan E. Small
Pamela Whitney Schaefer
Editors

 Springer

Neuroimaging Pharmacopoeia

Daniel Thomas Ginat • Juan E. Small
Pamela Whitney Schaefer
Editors

Neuroimaging Pharmacopoeia

 Springer

Editors

Daniel Thomas Ginat, MD, MS
Department of Radiology
University of Chicago
Pritzker Medical School
Chicago, IL
USA

Pamela Whitney Schaefer, MD
Department of Radiology
Massachusetts General Hospital
Harvard Medical School
Boston, MA
USA

Juan E. Small, MD
Department of Radiology
Lahey Clinic
Burlington, MA
USA

ISBN 978-3-319-12714-9 ISBN 978-3-319-12715-6 (eBook)
DOI 10.1007/978-3-319-12715-6
Springer Cham Heidelberg New York Dordrecht London

Library of Congress Control Number: 2015932672

© Springer International Publishing Switzerland 2015

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

The authors dedicate this book to the wonderful field of neuroradiology and head and neck imaging, the great advances and discoveries in pharmacology, and to a healthy and (illicit) drug-free world.



Foreword

What you have in front of you is a highly original, different, and useful publication and the only one of its kind in all of diagnostic radiology. The classic definition of “pharmacopoeia” is that of a book containing directions for the identification and preparation of drugs or a list of drugs and their uses. So, in a classic sense, this book is not a pharmacopoeia but something that goes beyond one. Each chapter describes one medication or drug and its indications and action mechanisms, and although in many instances this would suffice to be considered a pharmacopoeia, the authors go further and present a unique and complete series of high-quality neuroimaging studies that reflect the side effects and complications of the drugs discussed. It is, in my opinion, the best and most complete collection of this sort of images that I have even come across, and there is no question that it will be very helpful to neuroradiologists, radiologists, emergency physicians, and many others. Although are shorter than others, all 55 chapters are excellent. Just perusing through the images is fun, eye opening, and informative.

Dr. Schaefer, Small, and Ginat join many of the great, Avicenna, Galen, Vesalius and others who in the past have discussed the use of drugs in pharmacopoeias. My recommendations: buy the book- you will not be disappointed, look at the images- you will be entertained, read the book- you will be a better radiologist, and keep the book handy- you will help your patients.

Mauricio Castillo, MD, FACR
Professor of Radiology and Chief of Neuroradiology
University of North Carolina at Chapel Hill
Editor in Chief, American Journal of Neuroradiology
President, American Society of Neuroradiology

Preface

Various medicinal and illicit drugs can result in serious complications affecting the brain, head and neck, and spine. Many of these complications are visible on imaging. In addition, less serious complications or innocuous effects can result in diagnostic conundrums for the imaging interpreter unaware of the patient's drug exposures or their imaging manifestations, while others may produce rather characteristic changes on imaging that should be readily recognized as such. Until now, imaging interpreters have been unable to turn to a dedicated source of information relating to this subject. In this work, we have compiled a fairly comprehensive review of the imaging features of the effects of drugs and pharmaceuticals, from A to Z.

Considering the widespread use of medicinal and illicit drug use throughout the world, familiarity with this subject is critical for the imaging interpreter. Thus, the goal of *Neuroimaging Pharmacopoeia* is to serve as a resource for recognizing these effects and formulating an appropriate differential diagnosis. The term *pharmacopoeia* is derived from the two Greek words *pharmakon* for medicine and *poiein* to make. As such, a pharmacopeia is a compilation of medicinal or pharmacological drugs with their formulas, methods of preparation, effects, and directions of use.

This text represents an adaptation of the classical pharmacopeia, in which each chapter essentially comprises an illustrated pharmacological vignette comprising the indications, mechanism of action, discussion, differential diagnosis, and relevant figures for general classes or specific drugs. Although pharmacology is a dynamic field with perpetual development of new agents, this text provides a fundamental approach for understanding and interpreting neuroimaging studies in patients with drug-induced changes. This knowledge can in turn be used to help optimize patient management in certain cases.

Chicago, IL, USA
Burlington, MA, USA
Boston, MA, USA

Daniel Thomas Ginat, MD, MS
Juan E. Small, MD
Pamela Whitney Schaefer, MD

Acknowledgement

Alaa Jaly, Lancashire Teaching Hospitals

Chris Coutinho, MB, FRCR, Lancashire Teaching Hospitals

Jenny Hoang, MBBS, Duke University

Sachin Mathur, MRCP, FRCR, Lancashire Teaching Hospitals

Gregory Christoforidis, MD, University of Chicago

Alisa Gean, MD, University of California, San Francisco

Christine Glastonbury, MBBS, University of California, San Francisco

Vesna Petronic-Rosic, MD, University of Chicago

Caroline Robson, MBChB, Boston Children's Hospital

Contents

1 Tobacco Cigarette Smoking	1
Michael C. Veronesi and Daniel Thomas Ginat	
2 Alcohol	15
Michael C. Veronesi and Daniel Thomas Ginat	
3 Methanol	35
Allan Lee, Dee Nandurkar, and Ronil V. Chandra	
4 Cannabis (Marijuana)	41
Eileen C. Ang, Stephen L. Stuckey, Daniel Thomas Ginat, and Ronil V. Chandra	
5 Crack and Cocaine	49
Rania Hito and Daniel Thomas Ginat	
6 Amphetamines	59
Ronil V. Chandra, Daniel Thomas Ginat, and Juan E. Small	
7 Opioids	69
Daniel Thomas Ginat	
8 Betel Nuts	79
Grayson W. Hooper, Timothy Biega, and Daniel Thomas Ginat	
9 Licorice	83
Juan E. Small and Daniel Thomas Ginat	
10 Centella asiatica	87
Janu Pirakalathanan, Stephen L. Stuckey, and Ronil V. Chandra	
11 Nitrous Oxide (N₂O)	91
Daniel Thomas Ginat	
12 Iodinated Contrast Agents	95
Harut Haroyan and Daniel Thomas Ginat	
13 Gadolinium-Based Contrast Agents	105
Harut Haroyan and Daniel Thomas Ginat	
14 Pantopaque (Myodil, Iodophenylundecyclic Acid)	111
Daniel Thomas Ginat	

15 Thorium Dioxide (Thorotrast)	119
Daniel Thomas Ginat	
16 Bevacizumab (Avastin)	123
Daniel Thomas Ginat and William A. Mehan	
17 Temozolamide (Temodar)	131
William A. Mehan and Daniel Thomas Ginat	
18 1,3-Bis(2-Chloroethyl)-1-Nitrosourea (BCNU; Carmustine) Polymer Wafer (Gliadel)	137
Daniel Thomas Ginat	
19 Methotrexate	145
Daniel Thomas Ginat	
20 5-Fluorouracil	159
Daniel Thomas Ginat	
21 L-Asparaginase (Elspar/Erwinase)	163
Rania Hito and Ronil V. Chandra	
22 Ipilimumab (MDX-010, Yervoy)	169
Daniel Thomas Ginat and Gul Moonis	
23 Calcineurin Inhibitors	177
Santosh Shah and Daniel Thomas Ginat	
24 Bromocriptine (Parlodel) and Cabergoline (Dostinex)	189
Daniel Thomas Ginat	
25 Metronidazole (Flagyl)	197
Daniel Thomas Ginat	
26 Highly Active Antiretroviral Therapy (HAART)	203
Daniel Thomas Ginat	
27 Dilantin (Phenytoin Sodium)	213
Maria J. Borja and Daniel Thomas Ginat	
28 Valproic Acid (Sodium Valproate, Depakote)	219
Daniel Thomas Ginat	
29 Vigabatrin (Sabril)	223
Daniel Thomas Ginat	
30 Embolic Agents	231
Lee-Anne Slater, Daniel Thomas Ginat, and Ronil V. Chandra	
31 Aspirin and Plavix/Clopidogrel	241
Merav Galper, Daniel Thomas Ginat, and Juan E. Small	
32 Warfarin (Coumadin)	249
Jeffrey Hashim, Daniel Thomas Ginat, and Juan E. Small	
33 Heparin	257
Evan Watkins, Daniel Thomas Ginat, and Juan E. Small	

34 Tissue Plasminogen Activator (tPA)	261
Evan Watkins, Juan E. Small, and Daniel Thomas Ginat	
35 Supplemental Oxygen	263
Daniel Thomas Ginat	
36 Hypertonic Saline	271
Daniel Thomas Ginat	
37 Mannitol (1,2,3,4,5,6-Hexanehexol)	277
Daniel Thomas Ginat	
38 HiDAC (High-Dose Ara-C; Cytarabine; Cytosine Arabinoside; Cytosar-U; Depocyt)	281
Daniel Thomas Ginat	
39 Triple H Therapy	285
Daniel Thomas Ginat	
40 Insulin	289
Lee-Anne Slater, Stephen L. Stuckey, and Ronil V. Chandra	
41 Manganese in Total Parenteral Nutrition	293
Daniel Thomas Ginat	
42 Zinc Oxide (ZnO)	299
Daniel Thomas Ginat and Juan E. Small	
43 Angiotensin Converting Enzyme (ACE) Inhibitors	303
Daniel Thomas Ginat and Jason M. Johnson	
44 Acetazolamide (Diamox)	309
Daniel Lopes Noujaim, Juan E. Small, and Daniel Thomas Ginat	
45 Facial Fillers	313
Daniel Thomas Ginat and Charles J. Schatz	
46 Synthetic Corticosteroids	319
Jason M. Johnson, Yi Li, and Daniel Thomas Ginat	
47 Oral Contraceptives (Estrogen and Progestin)	329
Kimberly Kallianos, Daniel Thomas Ginat, and Jason M. Johnson	
48 Vaccines	335
Daniel Thomas Ginat	
49 Acetaminophen (Tylenol, Paracetamol)	341
Daniel Thomas Ginat	
50 Propofol	347
Mariam Aboian, Jason M. Johnson, and Daniel Thomas Ginat	
51 Bisphosphonates	351
Ana M. Franceschi, Daniel Thomas Ginat, and Jason M. Johnson	

52 Recombinant Human Bone Morphogenetic Protein	359
Marianne S. Reed, Jason M. Johnson, and Daniel Thomas Ginat	
53 Retinoids (13-cis-Retinoic Acid, Isotretinoin, Accutane, All-trans-retinoic acid)	363
Daniel Thomas Ginat	
54 Topical Prostaglandin Analogues	367
Daniel Thomas Ginat and Nurhan Torun	
55 Nasal Decongestants	371
Daniel Thomas Ginat	
Index	375

Contributors

Mariam Aboian, MD, Department of Radiology, University of California, San Francisco, CA, USA

Eileen C. Ang, MBBS, Department of Diagnostic Imaging, Monash Medical Center, Monash Health, Melbourne, VIC, Australia

Timothy Biega, MD, Department of Radiology, Tripler Army Medical Center, Honolulu, HI, USA

Maria J. Borja, MD, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA

Ronil V. Chandra, MBBS, MMed, FRANZCR, Department of Diagnostic Imaging, Monash Medical Center, Monash Health, Melbourne, VIC, Australia

Ana M. Franceschi, MD, Diagnostic Radiology, New York University Medical Center, New York, NY, USA

Merav Galper, MD, Department of Diagnostic Radiology, Lahey Clinic, Burlington, MA, USA

Daniel Thomas Ginat, MD, MS, Department of Radiology, University of Chicago, Pritzker Medical School, Chicago, IL, USA

Harut Haroyan, MD, Department of Radiology, University of Chicago, Chicago, IL, USA

Jeffrey Hashim, MD, Department of Diagnostic Radiology, Lahey Clinic, Burlington, MA, USA

Rania Hito, MD, Department of Radiology, University of Massachusetts Memorial Medical Center, Worcester, MA, USA

Grayson W. Hooper, DO, Department of Radiology, Tripler Army Medical Center, Honolulu, HI, USA

Jason M. Johnson, MD, Department of Diagnostic Radiology, MD Anderson Cancer Center, Houston, TX, USA

Kimberly Kallianos, MD, Department of Radiology, University of California, San Francisco, CA, USA

Allan Lee, MBBS, FRANZCR, Department of Diagnostic Imaging, Monash Medical Center, Monash Health, Melbourne, VIC, Australia

Yi Li, MD, Department of Radiology, University of California, San Francisco, CA, USA

William A. Mehan, MD, Department of Radiology, Tufts Medical Center, Boston, MA, USA

Gul Moonis, MD, Department of Radiology, Columbia University, New York, NY, USA

Dee Nandurkar, MBBS, FRANZCR, Department of Diagnostic Imaging, Monash Medical Center, Monash Health, Melbourne, VIC, Australia

Daniel Lopes Noujaim, MD, Department of Diagnostic Radiology, Lahey Clinic, Burlington, MA, USA

Janu Pirakalathanan, MBBS, Department of Diagnostic Imaging, Monash Medical Center, Monash Health, Melbourne, VIC, Australia

Marianne S. Reed, MD, Diagnostic Radiology, Yale University, New Haven, CT, USA

Pamela W. Schaefer, MD, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Charles J. Schatz, MD, FACR, Department of Radiology, Beverly Tower Wilshire Advanced Imaging, University of Southern California Keck School of Medicine, Los Angeles, CA, USA

Santosh Shah, MD, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA

Juan E. Small, MD, Department of Diagnostic Radiology, Lahey Clinic, Burlington, MA, USA

Lee-Anne Slater, MBBS, MMed, FRANZCR, Department of Diagnostic Imaging, Monash Medical Center, Monash Health, Melbourne, VIC, Australia

Stephen L. Stuckey, MBBS, MMed, MD, FRANZCR, Department of Diagnostic Imaging, Monash Medical Center, Monash Health, Melbourne, VIC, Australia

Nurhan Torun, MD, Department of Ophthalmology, Beth Israel Deaconess Medical Center, Boston, MA, USA

Michael C. Veronesi, MD, PhD, Department of Radiology, University of Chicago, Chicago, IL, USA

Evan Watkins, MD, Department of Diagnostic Radiology, Lahey Clinic, Burlington, MA, USA

Michael C. Veronesi and Daniel Thomas Ginat

1.1 Uses

Although tobacco use is legal, it is not recommended or prescribed for any therapeutic or medicinal purposes. It is smoked or chewed for recreational use as a potent temporary stimulant and mood elevator.

1.2 Mechanism

Nicotine, the primary active compound in cigarettes, is considered one of the most addictive of all substances because of its rapid onset and offset effects on the brain's dopamine reward systems. Inhaled nicotine can distribute in the brain within 10 s of inhalation but lasts mere seconds, causing a powerful urge for more. Of note, the long-term devastating sequela from smoking as it relates to neurologic disease are only partially explained by nicotine. Aside from nicotine, tobacco contains over six thousand other chemical compounds. In particular, polycyclic aromatic hydrocarbons and the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone have been implicated as the major

carcinogens associated with cigarette smoking. Additional details regarding the mechanisms of action for specific conditions are discussed in subsequent sections.

1.3 Discussion

Tobacco use is the leading cause of preventable death in the United States. An estimated 400,000 deaths or nearly one of every five deaths in the United States is associated with adverse conditions caused by smoking each year. Nearly every organ system is affected by cigarette smoking. The associated manifestations of cigarette smoking from a neuroimaging standpoint include the direct link between smoking and large vessels and lacunar infarcts, chronic small vessel ischemic disease, cerebral aneurysms, cerebral venous thrombosis, head and neck cancer of the squamous type, lung cancer metastases to the brain, and Warthin tumors.

1.3.1 Stroke

Compared with nonsmokers, cigarette smoking is estimated to increase the risk of stroke by 2–4-fold. Of note, stroke is the third leading cause of death in the United States with significant comorbidity in survivors. Mechanisms by which primary and second-hand tobacco smoke exposure increase the risk of stroke and heart disease

M.C. Veronesi, MD, PhD
Department of Radiology, University of Chicago,
Chicago, IL, USA

D.T. Ginat, MD, MS (✉)
Department of Radiology, University of Chicago,
Pritzker Medical School, Chicago, IL, USA
e-mail: ginatd01@gmail.com




Fig. 1.1 Embolic infarct. This smoker presented with acute left hemiplegia. Non-contrast axial CT image (a) shows a hypoattenuation within the right MCA territory

(arrow). 3D CTA image (b) shows occlusion of the right MCA (expected location *encircled*)

include carboxyhemoglobinemia, increased platelet aggregation, increased fibrinogen levels, reduced HDL cholesterol, and direct toxic effects of compounds such as 1,3-butadiene, a vapor phase constituent of environmental tobacco smoke that has been shown to accelerate atherosclerosis. Indeed, atherosclerosis and formation of both occlusive and embolic thrombi are the major causes of cerebrovascular accidents. Smoking is also associated with lacunar infarcts and chronic small vessel ischemic disease. Smoking cessation results in a considerable reduction in stroke risk.

On conventional angiography, CTA or MRA, atherosclerosis manifests as luminal narrowing that may be associated with calcifications. Acute embolic thrombus is suggested by intraluminal high attenuation on non-contrast CT, such as the hyperdense MCA sign, and manifests as an abrupt termination of the artery with absence of flow distally on CTA, MRA, or conventional angiography (Figs. 1.1). Hyperacute infarcts are often unapparent on non-contrast CT, but acute and early subacute infarcts can appear as areas

of hypoattenuation with loss of gray white matter differentiation and swelling. MRI with diffusion-weighted imaging is more sensitive for detecting early infarcts, which appear as areas of high T2 signal and restricted diffusion (Fig. 1.2). Besides smoking, other causes and risk factors for stroke include hypertension, hypercholesterolemia, diabetes, use of other drugs, such as cocaine and amphetamines (refer to Chaps. 5 and 6), dissection (Fig. 1.3), and vasculitis, such as lupus or Takayasu arteritis (Fig. 1.4). In addition to large territorial infarcts, smokers are prone to more extensive small vessel ischemic disease, which can manifest as areas of high T2 signal in the cerebral white matter (Fig. 1.5).

1.3.2 Cerebral Aneurysm

Besides smoking, additional risk factors that predispose to aneurysm formation include fenestrated arteries (Fig. 1.6), fibromuscular dysplasia, neurofibromatosis, alpha-1-antitrypsin deficiency, and




Fig. 1.2 Lacunar infarct and small vessel ischemic disease. The patient is a smoker who presented with acute neurological deficits. Axial FLAIR (a) and DWI (b) images show a recent right basal ganglia lacunar infarct (arrows). There is also diffuse, confluent periventricular

white matter T2 hyperintensity as well as mild scattered, punctate subcortical white matter T2 hyperintense foci without corresponding restricted diffusion, which is consistent with chronic small vessel ischemic disease




Fig. 1.3 Carotid dissection. Axial DWI (a) shows restricted diffusion in the left ACA-MCA watershed territory (arrowheads). The axial fat-suppressed T1 MRA (b)

shows hyperintensity surrounding the narrow left internal carotid artery flow void, compatible with intramural hemorrhage (arrow)




Fig. 1.4 Takayasu arteritis. Axial DWI (a) shows a focus of restricted diffusion in the left external capsule (arrows). MIP MRA (b) shows lack of flow-related enhancement

beyond the proximal common carotid arteries bilaterally (arrows)




Fig. 1.5 Cerebral aneurysm. A former 20-pack-year smoker underwent evaluation for a suspected stroke. Axial (a) and 3D volume rendered (b) CTA images show a left paraclinoid internal carotid artery saccular aneurysm

(arrow). There is also extensive atherosclerotic narrowing of the cerebral vasculature noted in both the anterior and posterior circulation bilaterally

connective tissue disorders, such as Ehlers-Danlos syndrome and Marfan's syndrome and polycystic kidney disease. Otherwise, the differential diagnosis of a cerebral aneurysm on radiologic imaging

includes an infundibulum (usually manifests as a triangular dilatation with the vessel arising from the apex that measures less than 2 mm), pseudoaneurysm, and mycotic aneurysm (Fig. 1.7).




Fig. 1.6 Arterial fenestration. Frontal projection 3D volume rendered CTA image (**a**) shows a fenestration of the proximal basilar artery (*arrow*). Lateral projection 3D

volume rendered CTA image (**b**) shows a dorsally oriented aneurysm arising from the caudal aspect of the fenestration (*arrowhead*)

1.3.3 Cerebral Venous Thrombosis

Secondary polycythemia due to chronic smoking is a risk factor developing cerebral venous thrombosis. Refer to the L-asparaginase and oral contraceptives chapters (Chaps. 21 and 47) for examples of venous thrombosis on imaging.

1.3.4 Head and Neck Cancer, Squamous Cell Carcinoma

Tobacco smoking, along with alcohol, is well established as the dominant risk factor for head and neck squamous cell carcinoma (HNSCC). This risk is correlated with the intensity and duration of tobacco use and is synergistic with concomitant alcohol consumption. There are more than sixty recognized compounds in tobacco that have a specific carcinogenic potential. In particular, nitrosamines and

polycyclic hydrocarbons can alter the molecular profile of an individual and causes mutations. Nicotine, originally thought only to be responsible for tobacco addiction, is also involved in tumor promotion and progression with antiapoptotic and indirect mitogenic properties. Other factors that can increase the risk of HNSCC include HPV infection and certain occupational exposures. Imaging with contrast-enhanced CT and MRI allows depiction of the anatomy of the larynx and submucosal tumor extension.

Dual-energy CT improves the diagnostic performance and interobserver reproducibility of evaluations of laryngeal cartilage invasion by squamous cell carcinoma. CT, MRI, and PET-CT also provide information regarding cervical nodal disease, systemic metastases, and synchronous malignancies.

On CT or MRI, head and neck squamous cell carcinomas often manifest as ill-defined enhancing masses. Aggressive features of




Fig. 1.7 Mycotic aneurysm. Axial CT image (a) shows left peri-rolandic hemorrhage. Axial MIP CTA image (b) shows a small outpouching arising from a cortical artery (*arrow*)

HNSCC include tissue invasion and necrosis (Fig. 1.8). The most common sites of head and neck squamous cell cancer are the floor of the mouth, tongue, soft palate, anterior tonsillar pillar, and retromolar trigone. In addition to locoregional spread, HNSCC can metastasize to distant organs hematogenously, most commonly to the lungs and bones. Metastasis to the brain is an infrequent, but carries a poor prognostic outcome (Fig. 1.9). Besides smoking, alcohol (refer to Chap. 2), betel nuts (refer to Chap. 8), and HPV are the other major risk factors for head and neck squamous cell carcinoma. Interestingly, HPV-positive squamous cell carcinomas generally have a more favorable prognosis and tend to have tumors that are relatively well-defined and large cystic nodal metastases (Fig. 1.10). Otherwise, the differential for other malignant cancers in the head and neck include thyroid cancer, lymphoma, salivary gland cancer, and sarcoma. Furthermore, head and neck abscesses can sometimes resemble necrotic or ulcerated head and neck

squamous cell carcinomas and nodal metastases (Fig. 1.11).

1.3.5 Brain Metastases

In addition to HNSCC, smoking has been shown to be a risk factor for the formation of several other types of cancers, including lung cancer, acute myeloid leukemia, bladder cancer, cervical cancer, renal cancer, esophageal cancer, gastric cancer, pancreatic cancer, and colorectal cancer. The majority of these cancers have at least some potential for metastasizing to the brain, which is the most feared complication of systemic malignancies. If no one smoked, one of every three cancer deaths in the United States would be avoided. Lung cancer has the highest association with smoking, causing an estimated 90 % of all lung cancer deaths in men and 80 % of all lung cancer deaths in women, and is the most common cancer that metastasizes to the brain. Nicotine-derived nitrosamine ketone (NNK) has